UroGen Pharma Stock Target Price and Analyst Consensus
| URGN Stock | USD 11.45 0.38 3.43% |
The current analyst and expert consensus on UroGen Pharma is Strong Buy, with 5 strong buy opinions. The current projected UroGen Pharma target price consensus is 39.93 with 6 analyst opinions. Check out Macroaxis Advice on UroGen Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.The most common way UroGen Pharma analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview UroGen Pharma executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on UroGen Pharma. We strongly encourage you to use your own analysis of UroGen Pharma to validate this buy or sell advice. UroGen Pharma buy-or-sell recommendation module provides average expert sentiment on the projected UroGen Pharma target price to derive its highest and lowest estimates based on projected price volatility of 2.9004.
Lowest Forecast 36.34 | Highest Forecast 44.32 | Target Price 39.93 |
UroGen |
It's important to approach UroGen Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
UroGen Pharma Target Price Consensus
UroGen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. UroGen Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most UroGen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand UroGen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of UroGen Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationUroGen Pharma Target Price Projection
UroGen Pharma's current and average target prices are 11.45 and 39.93, respectively. The current price of UroGen Pharma is the price at which UroGen Pharma is currently trading. On the other hand, UroGen Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
UroGen Pharma Market Quote on 18th of March 2025
Target Price
Analyst Consensus On UroGen Pharma Target Price
UroGen Pharma Analyst Ratings
UroGen Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about UroGen Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of UroGen Pharma's financials, market performance, and future outlook by experienced professionals. UroGen Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize UroGen Pharma price targets
UroGen Pharma's stock target price is an estimate of its future price, usually made by analysts. Using UroGen Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at UroGen Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if UroGen Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional UroGen Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of UroGen Pharma is a key component of UroGen Pharma valuation and have some predictive power on the future returns of a UroGen Pharma.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Macroaxis Picks Invested few shares | |
 | Blockchain Invested few shares | |
 | Business Services Invested few shares | |
 | Momentum Invested over 60 shares | |
 | Driverless Cars Invested few shares | |
 | SRI Sustainable Growth Invested over 40 shares | |
 | Apparel Invested over 40 shares | |
 | Casinos Sold over 90 shares | |
 | Basic Utilities Invested over 90 shares | |
Check out Macroaxis Advice on UroGen Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.